Cargando…
The Effect of Ivermectin on Cases of COVID-19()
Ivermectin is an antiviral agent that has historically had a wide variety of uses. Recently, it has gained popularity in the mainstream media for use in treating and preventing COVID-19 infection, prompting high sales in veterinary grade Ivermectin. Studies are increasingly looking at Ivermectin as...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212849/ https://www.ncbi.nlm.nih.gov/pubmed/35729025 http://dx.doi.org/10.1016/j.carrev.2022.06.004 |
_version_ | 1784730700336857088 |
---|---|
author | Annie, Frank H. Campbell, James Searls, Lauren Amos, Jessica |
author_facet | Annie, Frank H. Campbell, James Searls, Lauren Amos, Jessica |
author_sort | Annie, Frank H. |
collection | PubMed |
description | Ivermectin is an antiviral agent that has historically had a wide variety of uses. Recently, it has gained popularity in the mainstream media for use in treating and preventing COVID-19 infection, prompting high sales in veterinary grade Ivermectin. Studies are increasingly looking at Ivermectin as a possible agent for prevention and treatment of COVID-19, however further information is needed to assess efficacy and safety. Our project aimed to evaluate mortality differences in patients with COVID-19 infection who were prescribed Ivermectin vs. those not prescribed Ivermectin. Adult patients with active COVID-19 infection who were not prescribed Ivermectin (n = 797,285 Outpatient, n = 481,705 Inpatient, and n = 58,050 Intensive care unit), and those prescribed Ivermectin (n = 804 Outpatient, n = 1774 Inpatient, and n = 107 Intensive care unit) were evaluated. The cohorts were then evaluated for mortality comparing patients prescribed Ivermectin and those not prescribed Ivermectin in the Outpatient (7.7 % vs 2.2 %, P < 0.001), Inpatient not requiring Intensive Care (15.6 % vs 7.2 %, P ≤ 0.001), and Intensive care (20.6 % vs 19.6 %, P = 0.86) treatment settings. |
format | Online Article Text |
id | pubmed-9212849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92128492022-06-22 The Effect of Ivermectin on Cases of COVID-19() Annie, Frank H. Campbell, James Searls, Lauren Amos, Jessica Cardiovasc Revasc Med Research Letters Ivermectin is an antiviral agent that has historically had a wide variety of uses. Recently, it has gained popularity in the mainstream media for use in treating and preventing COVID-19 infection, prompting high sales in veterinary grade Ivermectin. Studies are increasingly looking at Ivermectin as a possible agent for prevention and treatment of COVID-19, however further information is needed to assess efficacy and safety. Our project aimed to evaluate mortality differences in patients with COVID-19 infection who were prescribed Ivermectin vs. those not prescribed Ivermectin. Adult patients with active COVID-19 infection who were not prescribed Ivermectin (n = 797,285 Outpatient, n = 481,705 Inpatient, and n = 58,050 Intensive care unit), and those prescribed Ivermectin (n = 804 Outpatient, n = 1774 Inpatient, and n = 107 Intensive care unit) were evaluated. The cohorts were then evaluated for mortality comparing patients prescribed Ivermectin and those not prescribed Ivermectin in the Outpatient (7.7 % vs 2.2 %, P < 0.001), Inpatient not requiring Intensive Care (15.6 % vs 7.2 %, P ≤ 0.001), and Intensive care (20.6 % vs 19.6 %, P = 0.86) treatment settings. Elsevier Inc. 2022-11 2022-06-17 /pmc/articles/PMC9212849/ /pubmed/35729025 http://dx.doi.org/10.1016/j.carrev.2022.06.004 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Research Letters Annie, Frank H. Campbell, James Searls, Lauren Amos, Jessica The Effect of Ivermectin on Cases of COVID-19() |
title | The Effect of Ivermectin on Cases of COVID-19() |
title_full | The Effect of Ivermectin on Cases of COVID-19() |
title_fullStr | The Effect of Ivermectin on Cases of COVID-19() |
title_full_unstemmed | The Effect of Ivermectin on Cases of COVID-19() |
title_short | The Effect of Ivermectin on Cases of COVID-19() |
title_sort | effect of ivermectin on cases of covid-19() |
topic | Research Letters |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212849/ https://www.ncbi.nlm.nih.gov/pubmed/35729025 http://dx.doi.org/10.1016/j.carrev.2022.06.004 |
work_keys_str_mv | AT anniefrankh theeffectofivermectinoncasesofcovid19 AT campbelljames theeffectofivermectinoncasesofcovid19 AT searlslauren theeffectofivermectinoncasesofcovid19 AT amosjessica theeffectofivermectinoncasesofcovid19 AT anniefrankh effectofivermectinoncasesofcovid19 AT campbelljames effectofivermectinoncasesofcovid19 AT searlslauren effectofivermectinoncasesofcovid19 AT amosjessica effectofivermectinoncasesofcovid19 |